Engasertib clinical trials
Also written VAD044.
How each study uses engasertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the engasertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Vaderis Therapeutics AG (3)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test engasertib.
- Jan 2027Assess Safety and Efficacy of VAD044 in HHT PatientsPhase 1/2 · Vaderis Therapeutics AG
Studies
Open first, then newest update. How each study uses engasertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)RecruitingPhase 3Vaderis Therapeutics AGNCT07743671Written as Engasertib
- Effect of a Known P-glycoprotein (P-gp) Inhibitor, Itraconazole, on the Pharmacokinetics (PK) of EngasertibCompletedPhase 1Vaderis Therapeutics AGNCT07800429Written as Engasertib
- Assess Safety and Efficacy of VAD044 in HHT PatientsActive, not recruitingPhase 1/2Vaderis Therapeutics AGNCT05406362Written as VAD044 Part I
Codes
What other systems call engasertib · ClinicalTrials.gg INT017003
- UNII (FDA) K2US8HW4TQENGASERTIBConfirmed FDA, Wikidata
- Wikidata Q140529156engasertibConfirmed FDA, Wikidata
- NCI Thesaurus C215735EngasertibOne source FDA
- DrugBank DB17697One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | K2US8HW4TQ | ENGASERTIB | Confirmed FDA, Wikidata |
| Wikidata | Q140529156 | engasertib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C215735 | Engasertib | One source FDA |
| DrugBank | DB17697 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.